CN113521258A - 一种改善衰老的组织注射液 - Google Patents
一种改善衰老的组织注射液 Download PDFInfo
- Publication number
- CN113521258A CN113521258A CN202110886509.0A CN202110886509A CN113521258A CN 113521258 A CN113521258 A CN 113521258A CN 202110886509 A CN202110886509 A CN 202110886509A CN 113521258 A CN113521258 A CN 113521258A
- Authority
- CN
- China
- Prior art keywords
- tissue
- skin
- injection
- glutathione
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 29
- 239000007924 injection Substances 0.000 title claims abstract description 29
- 230000032683 aging Effects 0.000 title claims abstract description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 39
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 27
- 102000008186 Collagen Human genes 0.000 claims abstract description 22
- 108010035532 Collagen Proteins 0.000 claims abstract description 22
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 22
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 22
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 22
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 21
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 20
- 108010024636 Glutathione Proteins 0.000 claims abstract description 18
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960003180 glutathione Drugs 0.000 claims abstract description 18
- 229960004194 lidocaine Drugs 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 18
- 108010087806 Carnosine Proteins 0.000 claims abstract description 16
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 16
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 16
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 15
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940105067 sodium chloride 9 mg/ml Drugs 0.000 claims abstract description 15
- 239000004471 Glycine Substances 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 230000035764 nutrition Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 4
- 229920002674 hyaluronan Polymers 0.000 abstract description 4
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 238000001243 protein synthesis Methods 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 230000014616 translation Effects 0.000 abstract description 4
- 206010033372 Pain and discomfort Diseases 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000008021 deposition Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 17
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 102000002020 Protease-activated receptors Human genes 0.000 description 1
- 108050009310 Protease-activated receptors Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种改善衰老的组织注射液,按照质量浓度计包括如下物质:胶原蛋白5‑10mg/ml;透明质酸钠4‑8mg/ml;氨甲环酸5‑10mg/ml;谷胱甘肽10‑30mg/ml;L‑肌肽2‑4mg/ml;甘氨酸0.1‑0.2mg/ml;脯氨酸0.2‑0.4mg/ml;利多卡因5‑10mg/ml;氯化钠9mg/ml。本发明通过增加胶原蛋白及透明质酸钠,能够快速补机体流失的蛋白及玻尿酸,同时形成组织腔隙刺激自体组织增生,促进注射部分组织丰盈,L‑肌肽,氨甲环酸、谷胱甘肽抗炎、抗氧化,提高皮肤对环境的适应性,减少色沉,使得皮肤更加健康有光泽,甘氨酸、脯氨酸增加蛋白合成营养,能够为皮肤组织细胞提供营养,美容效果更加持久。在注射过程中由于增了利多卡因,能够减少注射疼痛和不适感。
Description
技术领域
本发明属于美容注射液技术领域,具体涉及一种改善衰老的组织注射液。
背景技术
爱美是人类的天性,但是随着年龄的增加,皮肤随着年龄增长逐渐衰老,皮肤组织中蛋白流失,形成了皮肤干燥、色素沉着、皱纹增多的现状,年轻时有光泽、弹性的皮肤一去不复返。
为了让皮肤保持年轻态,现代社会中越来越多的人群选择通过药物注射方式来维持皮肤状态。目前的注射美容的方法通常采用胶原蛋白、玻尿酸填充,方式单一,效果有限。
发明内容
本发明的目的在于提供一种改善衰老的组织注射液,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:一种改善衰老的组织注射液,按照质量浓度计包括如下物质:
胶原蛋白5-10mg/ml;
透明质酸钠4-8mg/ml;
氨甲环酸5-10mg/ml;
谷胱甘肽10-30mg/ml;
L-肌肽2-4mg/ml;
甘氨酸0.1-0.2mg/ml;
脯氨酸0.2-0.4mg/ml;
利多卡因5-10mg/ml;
氯化钠9mg/ml。
本发明的有益效果在于:
胶原蛋白:当胶原蛋白注射入干瘪凹陷的皮肤后,脱水收缩重新排列,至近似于体内自然胶原纤维。促进体内成纤维细胞、毛细血管、脂肪细胞向胶原移植物内移行生长,并合成自身的胶原蛋白,终形成自身正常***,使凹陷回复,皱纹变浅或消失。
透明质酸钠:透明质酸钠是皮肤固有的生物物质,外源注射透明质酸钠通过促进表皮细胞的增殖和分化,以及清除氧自由基的作用,可促进受伤部位皮肤的再生。透明质酸钠水溶液具有较强的黏弹性和润滑性可减少水分流失,促进血液微循环,有利于皮肤对营养物质的吸收,从而防止皮肤老化,起到美容抗皱作用。
氨甲环酸:氨甲环酸是蛋白酶抑制剂,皮肤在受到紫外线照射后,氨甲环酸不仅能抑制酪氨酸酶酵素,还能抑制***素PGE2的释放,防止黑色素聚集。还能通过抑制蛋白酶活化受体的表达,从而阻止黑色素的转运和扩散。其退黑除斑的功效比维生素C高约50倍,是果酸的近10倍左右。
谷胱甘肽:谷胱甘肽具有相当高的对酪氨酸酶的抑制率,谷胱甘肽是一种抗氧化剂和自由基清除剂,其三肽结构中的活泼巯基可使酪氨酸酶中处于酶活力中心的二价铜还原为一价铜所致。从而减少黑色素的产生,达到美白功效。
L-肌肽:能促进细胞的新陈代谢,延缓衰老,防止糖基化的反应,肌肽可清除在氧化应激过程中使细胞膜的脂肪酸过度氧化而形成的活性氧自由基(ROS)具有抗氧化,与美白类成分搭配使用,增强其美白的功效。
甘氨酸脯氨酸:蛋白质合成的必备氨基酸,促进皮肤胶原蛋白的再生提供营养物质。
作为优选,按照质量浓度计包括如下物质:
胶原蛋白10mg/ml;
透明质酸钠8mg/ml;
氨甲环酸5mg/ml;
谷胱甘肽10mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。
作为优选,按照质量浓度计包括如下物质:
胶原蛋白5mg/ml;
透明质酸钠4mg/ml;
氨甲环酸10mg/ml;
谷胱甘肽30mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。
作为优选,按照质量浓度计包括如下物质:
透明质酸钠4mg/ml;
氨甲环酸5mg/ml;
谷胱甘肽20mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。
作为优选,按照质量浓度计包括如下物质:
胶原蛋白10mg/ml;
透明质酸钠6mg/ml;
氨甲环酸10mg/ml;
谷胱甘肽30mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。
本发明的技术效果和优点:
本发明通过增加胶原蛋白及透明质酸钠,能够快速补机体流失的蛋白及玻尿酸,同时形成组织腔隙刺激自体组织增生,促进注射部分组织丰盈,L-肌肽,氨甲环酸、谷胱甘肽抗炎、抗氧化,提高皮肤对环境的适应性,减少色沉,使得皮肤更加健康有光泽,甘氨酸、脯氨酸增加蛋白合成营养,能够为皮肤组织细胞提供营养,美容效果更加持久。在注射过程中由于增了利多卡因,能够减少注射疼痛和不适感。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种改善衰老的组织注射液,按照质量浓度计包括如下物质:
胶原蛋白10mg/ml;
透明质酸钠8mg/ml;
氨甲环酸5mg/ml;
谷胱甘肽10mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。用于填充额颞部。
实施例2
一种改善衰老的组织注射液,按照质量浓度计包括如下物质:
胶原蛋白5mg/ml;
透明质酸钠4mg/ml;
氨甲环酸10mg/ml;
谷胱甘肽30mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。用于填充面颊、颧部。
实施例3
一种改善衰老的组织注射液,按照质量浓度计包括如下物质:
透明质酸钠4mg/ml;
氨甲环酸5mg/ml;
谷胱甘肽20mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。用于填充面部真皮下。
实施例4
一种改善衰老的组织注射液,按照质量浓度计包括如下物质:
胶原蛋白10mg/ml;
透明质酸钠6mg/ml;
氨甲环酸10mg/ml;
谷胱甘肽30mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。用于填充手部。
改善衰老效果的测试
招募30名35-55岁的、肤色暗沉、干燥、细纹明显的女性志愿者,随机给予志愿者相应部位实施实施例(1-4),并给予3-6个月的随访,观察结果如下:
通过上述数据可知,通过对不同部位进行注射案例30例,观察3月至半年,志愿者肤色明显提亮、细纹明显改善、肤质改善,1例出现红肿,冰敷后症状消失,无其他不适应症状,效果稳定。
本发明通过增加胶原蛋白及透明质酸钠,能够快速补机体流失的蛋白及玻尿酸,同时形成组织腔隙刺激自体组织增生,促进注射部分组织丰盈,L-肌肽,氨甲环酸、谷胱甘肽抗炎、抗氧化,提高皮肤对环境的适应性,减少色沉,使得皮肤更加健康有光泽,甘氨酸、脯氨酸增加蛋白合成营养,能够为皮肤组织细胞提供营养,美容效果更加持久。在注射过程中由于增了利多卡因,能够减少注射疼痛和不适感。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种改善衰老的组织注射液,其特征在于:按照质量浓度计包括如下物质:
胶原蛋白5-10mg/ml;
透明质酸钠4-8mg/ml;
氨甲环酸5-10mg/ml;
谷胱甘肽10-30mg/ml;
L-肌肽2-4mg/ml;
甘氨酸0.1-0.2mg/ml;
脯氨酸0.2-0.4mg/ml;
利多卡因5-10mg/ml;
氯化钠9mg/ml。
2.根据权利要求1所述的一种改善衰老的组织注射液,其特征在于:按照质量浓度计包括如下物质:
胶原蛋白10mg/ml;
透明质酸钠8mg/ml;
氨甲环酸5mg/ml;
谷胱甘肽10mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。
3.根据权利要求1所述的一种改善衰老的组织注射液,其特征在于:按照质量浓度计包括如下物质:
胶原蛋白5mg/ml;
透明质酸钠4mg/ml;
氨甲环酸10mg/ml;
谷胱甘肽30mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。
4.根据权利要求1所述的一种改善衰老的组织注射液,其特征在于:按照质量浓度计包括如下物质:
透明质酸钠4mg/ml;
氨甲环酸5mg/ml;
谷胱甘肽20mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。
5.根据权利要求1所述的一种改善衰老的组织注射液,其特征在于:按照质量浓度计包括如下物质:
胶原蛋白10mg/ml;
透明质酸钠6mg/ml;
氨甲环酸10mg/ml;
谷胱甘肽30mg/ml;
L-肌肽2mg/ml;
甘氨酸0.1mg/ml;
脯氨酸0.2mg/ml;
利多卡因5mg/ml;
氯化钠9mg/ml。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110886509.0A CN113521258A (zh) | 2021-08-03 | 2021-08-03 | 一种改善衰老的组织注射液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110886509.0A CN113521258A (zh) | 2021-08-03 | 2021-08-03 | 一种改善衰老的组织注射液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113521258A true CN113521258A (zh) | 2021-10-22 |
Family
ID=78090303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110886509.0A Pending CN113521258A (zh) | 2021-08-03 | 2021-08-03 | 一种改善衰老的组织注射液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113521258A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114522223A (zh) * | 2022-03-24 | 2022-05-24 | 浙江天妍生物科技有限公司 | 一种纠正皮肤褶皱的注射液及其生产工艺 |
CN115591024A (zh) * | 2022-10-09 | 2023-01-13 | 深圳市科医美医疗投资有限公司(Cn) | 一种修复皮肤褶皱的注射液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104189952A (zh) * | 2014-08-05 | 2014-12-10 | 北京爱美客生物科技有限公司 | 纠正皮肤褶皱注射液及其制备方法 |
CN105535025A (zh) * | 2016-01-14 | 2016-05-04 | 无锡瑞博美容咨询服务有限公司 | 嫩肤美白营养液及嫩肤美白组合物 |
CN109528642A (zh) * | 2018-12-27 | 2019-03-29 | 上海欧邦医疗管理有限公司 | 一种自体修复营养注射液及其应用方法 |
-
2021
- 2021-08-03 CN CN202110886509.0A patent/CN113521258A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104189952A (zh) * | 2014-08-05 | 2014-12-10 | 北京爱美客生物科技有限公司 | 纠正皮肤褶皱注射液及其制备方法 |
CN105535025A (zh) * | 2016-01-14 | 2016-05-04 | 无锡瑞博美容咨询服务有限公司 | 嫩肤美白营养液及嫩肤美白组合物 |
CN109528642A (zh) * | 2018-12-27 | 2019-03-29 | 上海欧邦医疗管理有限公司 | 一种自体修复营养注射液及其应用方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114522223A (zh) * | 2022-03-24 | 2022-05-24 | 浙江天妍生物科技有限公司 | 一种纠正皮肤褶皱的注射液及其生产工艺 |
CN115591024A (zh) * | 2022-10-09 | 2023-01-13 | 深圳市科医美医疗投资有限公司(Cn) | 一种修复皮肤褶皱的注射液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Iorizzo et al. | Biorejuvenation: theory and practice | |
KR20120089433A (ko) | 충전제와 섬유아세포 성장 배지를 조합한 주사용 조성물 | |
CN113521258A (zh) | 一种改善衰老的组织注射液 | |
CN111110623A (zh) | 自体修复小小针营养液配方 | |
JP6726182B2 (ja) | 真皮結合組織中のフィブロエラスチンの回復用途のアミノ酸系組成物 | |
CN113679046B (zh) | 促进透明质酸与胶原蛋白相互作用的组合物及其应用 | |
CN111450010A (zh) | 一种具有抗初老功效的组合物及其在化妆品中的应用 | |
WO2014191056A1 (en) | Combination of active agents for treating skin aging | |
CN112120994A (zh) | 一种紧致弹力精华液及其制备方法和应用 | |
CN110538093A (zh) | 一种多肽修复液及其制备方法 | |
US20050084518A1 (en) | Health food containing hyaluronic acid and dermatan sulfate | |
FR2985183A1 (fr) | Composition cosmetique et dermatologique revitalisante | |
CN102349655A (zh) | 胶原蛋白多酚冲剂 | |
KR101305274B1 (ko) | 콜라겐 합성 촉진용 조성물 | |
CN111759762A (zh) | 祛黑眼圈组合物、精华及其制备方法 | |
KR101218898B1 (ko) | 콜라겐 합성 촉진용 조성물 | |
CN116509750A (zh) | 一种复合鱼胶原蛋白面膜液及制备方法 | |
CN114146018B (zh) | 保湿抗衰Polypeptides组合物、制备方法及含有其的面霜 | |
CN113813198A (zh) | 一种用于改善面部皱纹与紧致皮肤的营养液及制备方法 | |
CN111840127A (zh) | 一种兼具抗衰阻糖作用的自由基清除剂及制备方法 | |
TWI576117B (zh) | 玻尿酸產生促進劑 | |
CN111743812A (zh) | 一种***修复营养液及其制备方法 | |
CN109453085A (zh) | 一种可以去黑眼圈和水肿的组合物及其制备方法 | |
CN114698759A (zh) | 一种能淡化细纹的燕窝胶原蛋白肽饮品及其制备方法 | |
CN117731568A (zh) | 一种蓝睡莲冻干面膜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |